USITC: a powerful forum for biologics patent owners
Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
Plant variety rights in Mexico: sowing the seeds for better protection
A proposed amendment in Mexican law needs to be implemented urgently in order to adapt legislation to include provisions in accordance with the UPOV Convention, as Luz Flores of Uhthoff, Gómez Vega & Uhthoff reports.
Conference preview: Life Sciences IP Due Diligence 2018
A former Johnson & Johnson IP counsel and a retired judge are among the speakers at Life Sciences IP Due Diligence, on November 29 and 30 in Boston, as LSIPR finds out.
Arrow declarations: which way is the law pointing?
Depending on the facts and the content of the applications, an Arrow-type declaration could be made on grounds of insufficiency against divisional applications, say David Holt and Tony Proctor of Potter Clarkson.
New standards for stem cells
Costa Rica has released new rules for the clinical investigation of adult stem cells, as María del Pilar López and Esteban Monge of Zürcher Lawyers report.
The problems with patenting antibodies
Patenting antibodies across different jurisdictions can be a difficult task, as Kathy Coulter, senior IP counsel at Bristol-Myers Squibb, tells LSIPR.
A patent attack on three fronts
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
Conference preview: BIO-Europe 2018
BIO-Europe heads to Scandinavia for the first time, as Copenhagen plays host in November. LSIPR finds out more.
Conference preview: Life Science IP Forum, London
The issue of inefficiencies in the life sciences IP market is a hot topic to be discussed at the Life Science IP Forum in London in November, as LSIPR finds out.
IP and personalised medicine: a tailor-made approach
While personalised medicine is a challenging area for drug developers, there are a number of potential solutions, as LSIPR finds out.
